Crescent Biopharma officer sells 465 CBIO shares

CRESCENT BIOPHARMA, INC. officer Ryan Lynch reported an open-market sale of 465 Ordinary Shares on June 22, 2026 at a weighted average price of $17.99 per share.

Rhea-AI Filing Summary

CRESCENT BIOPHARMA, INC. officer Ryan Lynch reported an open-market sale of 465 Ordinary Shares on June 22, 2026 at a weighted average price of $17.99 per share. These shares were automatically sold to satisfy tax withholding obligations tied to the settlement of restricted stock units granted on December 15, 2025, under a pre-arranged Rule 10b5-1 instruction adopted on February 25, 2026. Following this tax-related sale, Lynch directly holds 13,871 Ordinary Shares.

Insider Trade Summary 10b5-1

Net Seller: 465 shares

Net Sell 1 txn

Insider Lynch Ryan

Role See Remarks

Sold 465 shs ($8K)

Type	Security	Shares	Price	Value
Sale	Ordinary Shares	465	$17.99	$8K

Holdings After Transaction: Ordinary Shares — 13,871 shares (Direct)

Footnotes (2)

1. F1. Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the settlement of restricted stock units granted to the Reporting Person on December 15, 2025. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the Reporting Person on February 25, 2026, solely with the intent to cover taxes in connection with the vesting of the restricted stock units.
2. F2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.88 to $18.86, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.

Key Figures

Shares sold: 465 shares Weighted average sale price: $17.99 per share Post-transaction holdings: 13,871 shares +3 more

6 metrics

Shares sold 465 shares Open-market sale on June 22, 2026

Weighted average sale price $17.99 per share Ordinary Shares sale on June 22, 2026

Post-transaction holdings 13,871 shares Direct ownership after June 22, 2026 sale

Sale price range $16.88–$18.86 per share Multiple transactions underlying weighted average price

RSU grant date December 15, 2025 Restricted stock units whose vesting triggered tax sale

Rule 10b5-1 instruction date February 25, 2026 Instruction adopted to cover RSU-related taxes

Key Terms

restricted stock units, tax withholding obligations, Rule 10b5-1, weighted average price

4 terms

restricted stock units financial

"in connection with the settlement of restricted stock units granted to the Reporting Person"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

tax withholding obligations financial

"shares automatically sold by the Reporting Person to satisfy tax withholding obligations"

Rule 10b5-1 regulatory

"sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction"

Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Crescent Biopharma (CBIO) report for Ryan Lynch?

Crescent Biopharma reported that officer Ryan Lynch sold 465 Ordinary Shares. The sale occurred on June 22, 2026 as an open-market transaction at a weighted average price of $17.99 per share to cover tax withholding on vested restricted stock units.

Why did Crescent Biopharma officer Ryan Lynch sell 465 CBIO shares?

The shares were sold automatically to satisfy tax withholding obligations. The transaction related to the settlement of restricted stock units granted on December 15, 2025, and was executed under a Rule 10b5-1 instruction specifically set up to cover related taxes.

Was the CBIO insider share sale by Ryan Lynch pre-planned under Rule 10b5-1?

Yes, the sale was executed under a Rule 10b5-1 instruction. The footnote states Lynch adopted this instruction on February 25, 2026, with the sole intent to cover taxes arising from the vesting of restricted stock units.

How many Crescent Biopharma (CBIO) shares does Ryan Lynch hold after the sale?

After the transaction, Ryan Lynch directly holds 13,871 Ordinary Shares. This post-transaction holding figure comes directly from the Form 4 and reflects his remaining direct ownership following the 465-share tax-related sale.

At what prices were Ryan Lynch’s CBIO shares sold on June 22, 2026?

The reported weighted average sale price was $17.99 per share. A footnote explains that individual trades occurred in multiple transactions at prices ranging from $16.88 to $18.86, inclusive, with full price breakdowns available upon request.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/23/2026 - 04:04 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lynch Ryan

(Last) (First) (Middle)

C/O CRESCENT BIOPHARMA, INC.

300 FIFTH AVENUE

(Street)

WALTHAM MASSACHUSETTS 02451

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CRESCENT BIOPHARMA, INC. [ CBIO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/22/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	06/22/2026		S		465(1)	D	$17.99(2)	13,871	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the settlement of restricted stock units granted to the Reporting Person on December 15, 2025. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the Reporting Person on February 25, 2026, solely with the intent to cover taxes in connection with the vesting of the restricted stock units.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.88 to $18.86, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.

Remarks:

Treasurer, Senior Vice President of Finance and Chief Accounting Officer.

	/s/ Barbara Bispham, as attorney-in-fact for Ryan Lynch	06/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)